ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1424	National Cancer Institute	Html	en	Liver (Hepatocellular) Cancer Screening (PDQ®)–Health Professional Version	Expert-reviewed information summary about tests used to detect or screen for liver (hepatocellular) cancer.	positive predictive value 0.503935 Needle aspiration cytology 0.492344 10-year survival rates 0.485559 hepatitis B virus 0.608203 hepatitis G infection 0.516552 control group 0.576587 6-monthly AFP assays 0.575205 North America 0.429041 nonalcoholic steatohepatitis 0.42282 AFP screening 0.526835 usual-care group 0.429439 ethnic groups 0.421496 test result 0.419937 HCC 0.942449 screening group 0.63461 Age-standardized incidence rates 0.541219 hepatitis B infection 0.498394 glycogen storage disease 0.517803 porphyria cutanea tarda 0.523911 new cases 0.427232 patients experience pain 0.502381 Serum AFP 0.49956 fetal-specific glycoprotein antigen 0.51455 United States 0.614175	screening tests 0.450593 retrospective case-control study 0.516703 mortality rate ratio 0.509505 certain Aspergillus species 0.510442 widely used tumor 0.501438 cryptogenic cirrhosis 0.452869 earlier diagnosis 0.555097 right upper quadrant 0.485875 common cancer 0.432709 surface antigen–positive carriers 0.524371 diagnosis study designs. 0.509206 Chinese Americans 0.422068 high incidence 0.419907 distinct male preponderance 0.54002 risk factor 0.421115 HCC mortality 0.712636 mortality rate 0.512472 randomized controlled trial 0.492498 alcoholic cirrhosis 0.45216 chronic hepatitis 0.816099 germ cell tumors 0.509004 liver biopsy 0.576034 annual risk 0.42449 liver cancer 0.48682	CLICK HERE
1453	National Cancer Institute	Html	en	Esophageal Cancer Prevention (PDQ®)–Health Professional Version	Expert-reviewed information summary about factors that may influence the risk of developing esophageal cancer and about research aimed at the prevention of this disease.	population-based case-controlled study 0.456088 Incidence rates 0.385333 symptomatic gastroesophageal reflux 0.449595 Barrett epithelium 0.458468 control group 0.467545 population attributable risk 0.450158 abnormal intestinal-type epithelium 0.466177 upper gastrointestinal hemorrhage 0.4271 GERD symptoms 0.44816 dysplastic Barrett esophagus 0.622479 distal esophagus 0.516913 case-control studies 0.466408 characteristic endoscopic appearance 0.435919 racial/ethnic groups 0.387576 alcohol abuse 0.441548 sham ablation 0.397202 patients 0.529714 incidence rate 0.442768 relative risk 0.448332 long-standing GERD 0.393778 esophageal adenocarcinoma 0.436843 esophageal adenocarcinoma. 0.389793 Retrospective cohort studies 0.444668 radiofrequency ablation 0.397459	new cases 0.385134 population-based cohort study 0.450776 esophageal cancer 0.543708 United States 0.381547 neoplastic alteration 0.380441 squamous epithelium. 0.390253 Barrett esophagus 0.930056 disease progression 0.441468 low-grade dysplasia 0.40734 significantly increased risk 0.448898 recurrent reflux symptoms 0.445059 important epidemiological difference 0.443496 black men 0.381968 case-control study 0.397548 high-grade dysplasia group 0.469185 adenocarcinoma 0.464553 certain GERD symptoms 0.4422 risk factor 0.383382 randomized controlled trial 0.433019 treatment group 0.414938 stratified squamous epithelium 0.484787 ablation group 0.497322 risk 0.45334 columnar epithelium 0.407571	CLICK HERE
1465	National Cancer Institute	Html	en	Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of childhood acute myeloid leukemia, myelodysplastic syndromes, and other myeloproliferative disorders.	cytogenetically normal AML 0.472151 acute myelogenous leukemia 0.566998 acute myeloid leukemias 0.479592 acute leukemia cells 0.490369 Mixed-phenotype acute leukemia 0.492893 pediatric AML chromosomal 0.458451 acute leukemias 0.458907 mutations 0.522652 myeloid leukemia patients 0.500607 leukemia group 0.471134 biphenotypic acute leukemia 0.49298 children 0.465 pediatric myeloid leukemia 0.49349 childhood AML 0.456416 chronic myelomonocytic leukemia 0.469481 AML 0.543947 World Health Organization 0.492048 CEBPA mutations 0.477251 leukemia development 0.468848 acute monocytic leukemia 0.483805 chronic myelogenous leukemia 0.468404 Acute myelomonocytic leukemia 0.489711 prognostic significance 0.496134 international retrospective study 0.454979 promyelocytic leukemia cases 0.462082	pediatric leukemia 0.454781 pediatric AML patients 0.456596 et al. 0.655126 acute megakaryoblastic leukemia 0.509773 normal pediatric AML 0.45551 myeloid neoplasms 0.47963 internal tandem duplication 0.460861 Br J Haematol 0.501425 acute promyelocytic leukaemia 0.457345 normal myeloid development 0.457734 acute myeloid leukemia 0.996934 acute myeloid leukaemia 0.513022 Leukemia Study Group 0.464981 juvenile myelomonocytic leukemia 0.495899 myeloid leukemia cells 0.495298 acute megakaryocytic leukemia 0.484055 mixed lineage leukemia 0.460628 Abstract 0.599778 Clin Oncol 0.480965 AML patients 0.464901 blood 0.501248 promyelocytic leukemia correlates 0.463064 acute promyelocytic leukemia 0.625964 pediatric AML 0.496596	CLICK HERE
1745	National Cancer Institute	Html	en	Radon and Cancer	A fact sheet about radon, an odorless radioactive gas, and its possible association with cancer, and how to test for radon in the home.	residential radon 0.562353 American case-control studies 0.256996 lung cancer 0.983232 radon test kit 0.445489 homes 0.263005 tiny radioactive particles 0.260576 radon risk 0.437726 indoor radon levels 0.492199 Lubin JH 0.260179 lung tumors 0.286182 long-term tests 0.254643 residential radon exposure 0.479323 average radon level 0.4525 slightly increased risk 0.263122 experimental animal studies 0.260434 radon gas 0.490329 radon programs 0.421637 radon exposure 0.485254 Environmental Protection Agency 0.303434 National Radon Hotline 0.443169 Radon Reduction 0.421521 radon testing 0.473889 radon 0.847228 National Radon 0.44518	United States 0.325125 radon causes lung 0.520748 radioactive gas 0.261736 high radon levels 0.476793 U.S. Environmental Protection 0.30233 underground uranium miners 0.261056 radon mitigation promotion 0.443958 normal decay 0.26025 low levels outdoors 0.269932 radon studies 0.441219 highest radon levels 0.486865 German uranium miners 0.256763 different indoor radon 0.45539 radioactive particles 0.292648 radon levels 0.737469 Health Physics 0.256943 Radon Program Services 0.446453 radon-related cancer deaths 0.313801 lung cancer deaths 0.435124 lung cancer risk 0.337519 local radon official 0.450897 elements uranium 0.296591 National Radon Hotlines 0.444919 et al 0.254717	CLICK HERE
1962	National Cancer Institute	Html	es	Tratamiento de las neoplasias mielodisplásicas o mieloproliferativas (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de las neoplasias mielodisplásicas o mieloproliferativas, incluso las leucemias mielomonocíticas crónicas o juveniles, y la LMC atípica.	siguientes procedimientos 0.310473 células madre 0.796441 cuidado médico 0.302013 leucemia aguda 0.308416 células madre formadoras 0.309431 hueso compacto 0.314757 enlace drugs approved 0.312251 cromosoma filadelfia 0.309322 célula madre mieloide 0.313237 células anormales.ampliar aspiración 0.315092 National Cancer Institute 0.302184 siguientes riesgos 0.301804 leucemia mielomonocítica 0.520866 Instituto Nacional 0.307834 célula madre linfoide 0.331173	PDQ Tratamiento 0.305968 neurofibromatosis tipo 0.303576 células madre mieloide 0.322767 leucemia mielógena 0.392932 neoplasias mielodisplásicas 0.970229 Physician Data Query 0.30823 neoplasia mielodisplásica 0.36973 Myeloproliferative Neoplasms 0.306895 siguientes enlaces 0.302219 célula madre 0.398378 células sanguíneas maduras 0.374442 neoplasias mieloproliferativas 0.31703 ósea elabora células 0.32181 siguientes pruebas 0.312083 siguientes sumarios 0.307642	CLICK HERE
2036	National Cancer Institute	Html	es	Tratamiento de las neoplasias mieloproliferativas crónicas (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de las neoplasias mieloproliferativas crónicas.	siguientes procedimientos 0.417826 células madre 0.649424 siguientes aspectos 0.405563 leucemia aguda 0.417682 cuerpo.ampliar trasplante 0.403016 hueso compacto 0.418199 genes mpl 0.404719 enlace drugs approved 0.416336 célula madre mieloide 0.431519 genes jak2 0.404899 Sudores nocturnos 0.404299 células anormales.ampliar aspiración 0.420044 National Cancer Institute 0.401966 siguientes riesgos 0.401801 Instituto Nacional 0.403647 célula madre linfoide 0.432844	PDQ Tratamiento 0.431983 leucemia mielógena 0.471893 Drugs Approved 0.417258 Physician Data Query 0.407937 llamada mielofibrosis 0.427648 serios problemas 0.403469 Myeloproliferative Neoplasms 0.417257 siguientes sustancias 0.403598 policitemia vera 0.696975 leucemia mieloide aguda 0.414565 gen jak2 0.405058 célula madre 0.501376 células sanguíneas maduras 0.468721 neoplasias mieloproliferativas 0.925417 siguientes pruebas 0.407534	CLICK HERE
3431	National Cancer Institute	Html	es	Dietilestilbestrol (DES) y el cáncer	Hoja informativa sobre el DES (una versión sintética del estrógeno) y los problemas de salud en los niños que estuvieron expuestos al DES en la matriz.	hormona femenina estrógeno 0.312636 Hatch EE 0.454515 DES problemas 0.383286 Urogenital abnormalities 0.305699 Diethylstilbestrol contraindicated 0.311242 exposed to diethylstilbestrol 0.406175 Cell Cancer Registry 0.312383 British Journal 0.315496 defectos congénitos 0.317789 reproductive characteristics 0.305946 Noller KL 0.315866 related synthetic hormones 0.309521 Prenatal diethylstilbestrol 0.312976 diethylstilbestrol during pregnancy 0.315088 Environmental Health 0.313238 posibles efectos 0.334954 Internal Medicine 0.305939 Estados Unidos 0.328505 DES Follow-up Study 0.443119 abortos espontáneos 0.319323 NCI Mamografías 0.30661 resultados contradictorios 0.314367 long-term health effects 0.309445 PubMed Abstract 0.959102 International Journal 0.31496	Cancer Control 0.307472 Carcinogénesis Hormonal Transplacentaria 0.310163 DES daughters 0.375119 given diethylstilbestrol 0.321239 cohort study 0.315559 Titus-Ernstoff L 0.382214 Hormonal Transplacental Carcinogenesis 0.31001 mayores riesgos 0.313929 Environmental Health Sciences 0.309128 Troisi R 0.359524 Hoover RN 0.313827 stilbestrol therapy with 0.308895 FDA Drug Bulletin 0.308403 to diethylstilbestrol alters 0.318831 Verloop J 0.312608 cuello uterino 0.526442 Public Relations Committee 0.308493 exposed prenatally 0.313265 to des 0.379155 riesgos instantáneos porcentaje 0.310067 menopausia prematura 0.316803 to diethylstilbestrol 0.546373 New England Journal 0.327355 DES Porcentaje 0.382487	CLICK HERE
3451	National Cancer Institute	Html	en	Planning the Transition to End-of-Life Care in Advanced Cancer (PDQ®)–Patient Version	Expert-reviewed information summary about the preparation needed by health care providers, patients, and families for the transition to end-of-life care in advanced cancer.	CPR 0.551685 end-of-life decisions 0.505947 treatments 0.539675 PDQ cancer information 0.625539 Out-of-hospital DNR order 0.511763 health care team 0.497649 clinical trials 0.511926 wishes 0.516111 health care providers 0.549541 emergency medical workers 0.548212 cancer information summary 0.569329 health care professionals 0.505787 family members 0.526957 patients 0.489953 end-of-life care options 0.519094 symptoms 0.496271 NCI PDQ cancer 0.514682 new chemotherapy treatment 0.48923 doctors 0.602249 supportive care 0.525701 life-saving procedures 0.497748 care 0.924816 end-of-life care 0.782032 treatment 0.671878	DNR order 0.576468 Palliative Care Organization 0.500652 breathing stops 0.496404 palliative care 0.693314 Cancer Information Service 0.494158 Health care proxy 0.49362 cardiopulmonary resuscitation 0.54384 hospice care 0.526131 National Cancer Institute 0.571506 decisions 0.647069 Advance directives 0.611485 health care 0.652677 Palliative Care Editorial 0.541845 advanced cancer 0.542943 Cancer Care page 0.510244 Care Editorial Board 0.540113 PDQ summary 0.57393 doctor 0.567646 end stages 0.495403 breathing machine 0.491509 cancer information summaries 0.492454 comprehensive cancer information 0.492895 cancer 0.776389 information 0.649786	CLICK HERE
3518	National Cancer Institute	Html	en	Use of Placebos	Information about placebos and their role in cancer clinical trials.	new treatment 0.545554 study 0.364583 patients 0.362034 medicine 0.367624 way 0.414648 treatment group 0.529513 to. 0.361225	doctors 0.371883 treatment clinical trials 0.815475 bias 0.382394 Placebos 0.570523 standard treatment 0.968379 cancer 0.37398	CLICK HERE
3676	National Cancer Institute	Html	en	Genomic Data Access	Information for NIH staff and extramural investigators on how to get a dbGaP account and how to request controlled-access data.	Supplementary Instructions 0.508326 trainees 0.351501 data use limitations 0.53645 access request form 0.751577 permanent employees 0.518968 cancer genotype-phenotype studies 0.653287 dbgap datasets 0.7932 Laboratory staff 0.513494 dbGaP Project Request 0.758272 Minimum Qualifications 0.520392 institution 0.370914 staff member 0.507438 database 0.339571 oversight 0.341561 responsibilities 0.337646 Extramural investigators 0.646629 postdoctoral fellows 0.532793 eRA Commons 0.541518 Applicants 0.337875 laboratory administration 0.514783 data access request 0.968754 NIH staff 0.519235 PIs 0.358599	tenure-track professor 0.518153 NCI Data Access 0.741329 signature approvals 0.518117 Eligibility requirements 0.511168 results 0.339375 email 0.333649 dbGaP Authorized Access 0.761069 seniorscientist 0.335515 Access Individual-Level Data 0.77002 principal investigators 0.705009 genotypes 0.422884 pre-existing account 0.549785 data access requests 0.732725 dbGaP Request Procedures 0.709981 graduate students 0.515113 phenotypes 0.420428 DAR 0.341157 access permission form 0.755217 project requests 0.50912 Investigators Requesting Authorized 0.770653 interaction 0.333238 access form 0.569266 online 0.337555	CLICK HERE